The Journal of Thoracic and Cardiovascular Surgery
Volume 126, Issue 1 , Pages 17-25 , July 2003

Value of accelerated multimodality therapy in stage IIIA and IIIB non–small cell lung cancer

Read at the Eighty-second Annual Meeting of The American Association for Thoracic Surgery, Washington, DC, May 5-8, 2002.

  • Malcolm M DeCamp, MD

      Affiliations

    • From the Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • the Transplant Center, Division of Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA,
    • Corresponding Author InformationAddress for reprints: Malcolm M. DeCamp, MD, The Cleveland Clinic Foundation, 9500 Euclid Avenue/Desk F25, Cleveland, OH 44195, USA
    • ,
  • Thomas W Rice, MD

      Affiliations

    • From the Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • David J Adelstein, MD

      Affiliations

    • Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Mark A Chidel, MD

      Affiliations

    • Department of Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Lisa A Rybicki, MS

      Affiliations

    • Department of Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA.
    • ,
  • Sudish C Murthy, MD, PhD

      Affiliations

    • From the Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Eugene H Blackstone, MD

      Affiliations

    • From the Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • the Transplant Center, Division of Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, USA,
    • Department of Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Received 9 May 2002 ,Accepted 14 January 2003.

References 

  1. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer (mature results of Southwest Oncology Group phase II study 8805). J Clin Oncol. 1995;13:1880–1892
  2. Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, et al.  Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 1997;15:712–722
  3. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al.  Survival of patients with resected N2 non-small-cell lung cancer (evidence for a subclassification and implications). J Clin Oncol. 2000;18:2981–2989
  4. Rice TW, Adelstein DJ, Koka A, Tefft M, Kirby TJ, Van Kirk MA, et al.  Accelerated induction therapy and resection for poor prognosis stage III non–small cell lung cancer. Ann Thorac Surg. 1995;60:586–591
  5. Rice TW, Adelstein DJ, Ciezki JP, Becker ME, Rybicki LA, Farver CF, et al.  Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer. Ann Thorac Surg. 1998;66:1909–1914
  6. Thames HD, Peters LJ, Withers HR, Fletcher GH. Accelerated fractionation vs hyperfractionation (rationales for several treatments per day). Int J Radiat Oncol Biol Phys. 1983;9:127–138
  7. Withers HR. Biologic basis for altered fractionation schemes. Cancer. 1985;55:2086–2095
  8. American Joint Committee on Cancer . AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002;
  9. Blackstone EH, Naftel DC, Turner ME. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Stat Assoc. 1986;81:615–624
  10. Kirklin JW, Barratt-Boyes BG. In: Cardiac surgery. 2nd ed. New York: Churchill Livingstone; 1993;p. 249
  11. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR. Results of cancer and leukemia group B protocol 8935.A multiinstitutional phase II trimodality trial for stage IIIA (N2)non-small-cell lung cancer. Cancer and Leukemia Group B ThoracicSurgery Group. J Thorac CardiovascSurg. 1995;109:473–483
  12. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, et al.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–680
  13. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–158
  14. Pitz CC, Maas KW, Van Swieten HA, de la Riviere AB, Hofman P, Schramel FM. Surgery as part of combined modality treatment in stage IIIB non–small cell lung cancer. Ann Thorac Surg. 2002;74:164–169
  15. Grunenwald DH, Andre F, Le Pechoux C, Girard P, Lamer C, Laplanche A, et al.  Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non–small cell lung cancer. J Thorac Cardiovasc Surg. 2001;122:796–802
  16. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–1717
  17. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al.  Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137
  18. Breiman L. Bagging predictors. Machine Learning. 1996;26:123–140

PII: S0022-5223(03)00206-X

doi: 10.1016/S0022-5223(03)00206-X

The Journal of Thoracic and Cardiovascular Surgery
Volume 126, Issue 1 , Pages 17-25 , July 2003

Article Tools

* Image Usage & Resolution